Abstract
This clinical study reports that blood levels of the pro-inflammatory mediator platelet-activating factor (PAF) did not change in colorectal cancer patients. In contrast, plasma levels of two enzymatic activities, one implicated in PAF production (i.e. phospholipase A2) and one in PAF degradation (i.e. PAF acetylhydrolase activity) were significantly elevated.
Full Text
The Full Text of this article is available as a PDF (100.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Denizot Yves, Gainant Alain, Guglielmi Laurence, Bouvier Stephane, Cubertafond Pierre, Mathonnet Murielle. Tissue concentrations of platelet-activating factor in colorectal carcinoma: inverse relationships with Dukes' stage of patients. Oncogene. 2003 Oct 16;22(46):7222–7224. doi: 10.1038/sj.onc.1207032. [DOI] [PubMed] [Google Scholar]
- Montrucchio G., Sapino A., Bussolati B., Ghisolfi G., Rizea-Savu S., Silvestro L., Lupia E., Camussi G. Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol. 1998 Nov;153(5):1589–1596. doi: 10.1016/S0002-9440(10)65747-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nevalainen T. J. Serum phospholipases A2 in inflammatory diseases. Clin Chem. 1993 Dec;39(12):2453–2459. [PubMed] [Google Scholar]
- Ogawa M., Yamashita S., Sakamoto K., Ikei S. Elevation of serum group II phospholipase A2 in patients with cancers of digestive organs. Res Commun Chem Pathol Pharmacol. 1991 Nov;74(2):241–244. [PubMed] [Google Scholar]